Abstract
The leap from laboratory to marketplace represents the critical chasm in longevity technology innovation. While scientific breakthroughs in aging biology continue to accelerate (López-Otín et al., 2023; DePinho et al., 2024), the commercialization pathway remains fragmented, creating a unique "valley of death" where promising discoveries often fail to reach consumers despite substantial investment interest (Campisi et al., 2019). At stake is a projected $46.62 billion market by 2033 (Business Research Insights, 2024) that could revolutionize healthcare by shifting from disease treatment to prevention of aging itself—potentially the most transformative healthcare paradigm since antibiotics (Deloitte, 2024). The implications of successful longevity technology commercialization extend far beyond the healthcare sector, as increased lifespans would necessitate dramatic changes in workforce participation to compensate for declining new entrants to the labor force (Papapetrou & Tsalaporta, 2020), restructuring of pension and insurance systems that collectively manage trillions of dollars (Amaglobeli et al., 2019), and fundamental adjustments to social structures across developed economies (Grand View Research, 2024).

This publication has 14 references indexed in Scilit: